In the BioHarmony Drug Report Database

"Preview" Icon

Lusutrombopag

Mulpleta, Lusutrombopag Shionogi, Mulpleo (lusutrombopag) is a small molecule pharmaceutical. Lusutrombopag was first approved as Mulpleta on 2018-07-31. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. The pharmaceutical is active against thrombopoietin receptor. Mulpleta’s patents are valid until 2031-09-29 (FDA).

 

Trade Name

 

Lusutrombopag Shionogi, Mulpleo
 

Common Name

 

lusutrombopag
 

ChEMBL ID

 

CHEMBL2107831
 

Indication

 

thrombocytopenia
 

Drug Class

 

Thrombopoetin agonists

Image (chem structure or protein)

Lusutrombopag structure rendering